ATE330611T1 - Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung - Google Patents
Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendungInfo
- Publication number
- ATE330611T1 ATE330611T1 AT01918763T AT01918763T ATE330611T1 AT E330611 T1 ATE330611 T1 AT E330611T1 AT 01918763 T AT01918763 T AT 01918763T AT 01918763 T AT01918763 T AT 01918763T AT E330611 T1 ATE330611 T1 AT E330611T1
- Authority
- AT
- Austria
- Prior art keywords
- cephalotaxine
- agents
- alkaloid
- hydroxy
- host
- Prior art date
Links
- YMNCVRSYJBNGLD-KURKYZTESA-N cephalotaxine Chemical class C([C@@]12C=C([C@H]([C@H]2C2=C3)O)OC)CCN1CCC2=CC1=C3OCO1 YMNCVRSYJBNGLD-KURKYZTESA-N 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 230000001028 anti-proliverative effect Effects 0.000 abstract 2
- 230000001413 cellular effect Effects 0.000 abstract 2
- DSRNKUZOWRFQFO-UHFFFAOYSA-N cephalotaxine Natural products COC1=CC23CCCN2CCc4cc5OCOc5cc4C3=C1O DSRNKUZOWRFQFO-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 101710172711 Structural protein Proteins 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000138 intercalating agent Substances 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 abstract 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000002212 purine nucleoside Substances 0.000 abstract 1
- 239000002718 pyrimidine nucleoside Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18969900P | 2000-03-15 | 2000-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE330611T1 true ATE330611T1 (de) | 2006-07-15 |
Family
ID=22698410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01918763T ATE330611T1 (de) | 2000-03-15 | 2001-03-15 | Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US6734178B2 (enExample) |
| EP (1) | EP1263440B1 (enExample) |
| JP (1) | JP4929436B2 (enExample) |
| AT (1) | ATE330611T1 (enExample) |
| AU (2) | AU4580301A (enExample) |
| CA (1) | CA2402710A1 (enExample) |
| DE (1) | DE60120928T2 (enExample) |
| DK (1) | DK1263440T3 (enExample) |
| ES (1) | ES2267741T3 (enExample) |
| PT (1) | PT1263440E (enExample) |
| WO (1) | WO2001068098A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2402710A1 (en) * | 2000-03-15 | 2001-09-20 | Chemgenex Therapeutics, Inc. | Use of a cephalotaxine and an antiproliferative agent in treating cellular proliferative disease |
| ATE305312T1 (de) * | 2000-04-12 | 2005-10-15 | Chemgenex Pharmaceuticals Inc | Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten |
| US20060211648A1 (en) * | 2000-04-12 | 2006-09-21 | Chemgenex Pharmaceuticals, Inc. | Naphthalimide compositions and uses thereof |
| US7135481B2 (en) | 2000-04-12 | 2006-11-14 | Chemgenex Pharmaceuticals, Inc. | Naphthalimide compositions and uses thereof |
| US20050170015A1 (en) * | 2000-10-31 | 2005-08-04 | Brown Dennis M. | Antiproliferative colchicine compositions and uses thereof |
| US20020123469A1 (en) * | 2000-10-31 | 2002-09-05 | Brown Dennis M. | Antiproliferative colchicine compositions and uses thereof |
| DE60313754T2 (de) * | 2002-03-06 | 2008-01-24 | The Medical Research and Education Trust, San Diego | Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin |
| AU2003253872A1 (en) * | 2002-07-17 | 2004-02-09 | Chemgenex Pharmaceuticals, Inc. | Formulations and methods of administration of cephalotaxines, including homoharringtonine |
| ES2572145T3 (es) * | 2002-07-22 | 2016-05-30 | Teva Pharmaceuticals Int Gmbh | Inhibición de la angiogénesis mediante alcaloides de cefalotoxina, derivados, composiciones y usos de los mismos |
| CN100396286C (zh) * | 2002-12-30 | 2008-06-25 | 北京大学第一医院 | 高三尖杉酯碱和三尖杉酯碱在制备抑制血管生成药物中的应用 |
| US20050288310A1 (en) * | 2004-06-04 | 2005-12-29 | Chemgenex Pharmaceuticals, Inc. | Methods of treating cellular proliferative disease using naphthalimide and PARP-1 inhibitors |
| US20060193893A1 (en) * | 2005-02-10 | 2006-08-31 | Chemgenex Pharmaceuticals, Inc. | Medical devices |
| WO2008128191A2 (en) * | 2007-04-13 | 2008-10-23 | Chemgenex Pharmaceuticals, Inc. | Oral cephalotaxine dosage forms |
| EP2260041A4 (en) | 2008-03-03 | 2012-04-25 | Sloan Kettering Inst Cancer | CEPHALOTAXUS ESTERS, METHOD FOR THEIR SYNTHESIS AND USES THEREOF |
| CN118217301B (zh) * | 2024-03-28 | 2025-08-05 | 宁波大学附属人民医院 | 一种协同治疗aml的含有8-氯腺苷和高三尖杉酯碱的药物组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399282A (en) * | 1979-07-10 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives |
| US4675318A (en) * | 1985-05-28 | 1987-06-23 | Yaguang Liu | Safe antileukemia drug, SAL |
| US5391745A (en) * | 1992-07-23 | 1995-02-21 | Sloan-Kettering Institute For Cancer Research | Methods of preparation of camptothecin analogs |
| CA2402710A1 (en) * | 2000-03-15 | 2001-09-20 | Chemgenex Therapeutics, Inc. | Use of a cephalotaxine and an antiproliferative agent in treating cellular proliferative disease |
| ATE305312T1 (de) * | 2000-04-12 | 2005-10-15 | Chemgenex Pharmaceuticals Inc | Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten |
-
2001
- 2001-03-15 CA CA002402710A patent/CA2402710A1/en not_active Abandoned
- 2001-03-15 AU AU4580301A patent/AU4580301A/xx active Pending
- 2001-03-15 DK DK01918763T patent/DK1263440T3/da active
- 2001-03-15 DE DE60120928T patent/DE60120928T2/de not_active Expired - Lifetime
- 2001-03-15 AU AU2001245803A patent/AU2001245803B8/en not_active Ceased
- 2001-03-15 AT AT01918763T patent/ATE330611T1/de active
- 2001-03-15 US US09/810,527 patent/US6734178B2/en not_active Expired - Lifetime
- 2001-03-15 PT PT01918763T patent/PT1263440E/pt unknown
- 2001-03-15 ES ES01918763T patent/ES2267741T3/es not_active Expired - Lifetime
- 2001-03-15 EP EP01918763A patent/EP1263440B1/en not_active Expired - Lifetime
- 2001-03-15 WO PCT/US2001/008480 patent/WO2001068098A2/en not_active Ceased
- 2001-03-15 JP JP2001566662A patent/JP4929436B2/ja not_active Expired - Fee Related
-
2004
- 2004-01-30 US US10/769,638 patent/US20040185117A1/en not_active Abandoned
-
2010
- 2010-04-15 US US12/761,251 patent/US20110008307A1/en not_active Abandoned
-
2011
- 2011-12-23 US US13/336,917 patent/US20120207855A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1263440B1 (en) | 2006-06-21 |
| ES2267741T3 (es) | 2007-03-16 |
| AU2001245803B2 (en) | 2005-12-15 |
| CA2402710A1 (en) | 2001-09-20 |
| AU2001245803B8 (en) | 2006-02-02 |
| JP2003526667A (ja) | 2003-09-09 |
| DK1263440T3 (da) | 2006-10-23 |
| HK1052138A1 (en) | 2003-09-05 |
| WO2001068098A2 (en) | 2001-09-20 |
| US6734178B2 (en) | 2004-05-11 |
| DE60120928T2 (de) | 2007-02-08 |
| EP1263440A2 (en) | 2002-12-11 |
| PT1263440E (pt) | 2006-11-30 |
| WO2001068098A3 (en) | 2002-06-06 |
| DE60120928D1 (de) | 2006-08-03 |
| AU4580301A (en) | 2001-09-24 |
| US20120207855A1 (en) | 2012-08-16 |
| US20110008307A1 (en) | 2011-01-13 |
| US20020032190A1 (en) | 2002-03-14 |
| US20040185117A1 (en) | 2004-09-23 |
| JP4929436B2 (ja) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE330611T1 (de) | Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung | |
| NO20020662D0 (no) | Pyrimidin-2,4,6-trion metalloproteinase inhibitorer | |
| BR0010220A (pt) | Compostos de pirimidinona | |
| CA2400554A1 (en) | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors | |
| NO985376L (no) | Kinolinkarboksamider som TNF-inhibitorer og som PDA-IV inhibitorer | |
| WO2002010764A3 (en) | SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY | |
| TR200002355T2 (tr) | 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri | |
| AP2001002319A0 (en) | Pyrimidine-2,4,6-trione metalloproteinase inhibitors. | |
| DE60113666T2 (de) | Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten | |
| ES2136137T3 (es) | Controles internos para reacciones de amplificacion isotermica de acidos nucleicos. | |
| WO2000066180A3 (en) | Method for enhancing contrast produced by mri | |
| PT1032575E (pt) | Derivados de 2,3-diaril-pirazolo(1,5-b)pirimidinas sua preparacao e seu uso como inibidores de ciclooxigenase 2 (cox-2) | |
| ATE345682T1 (de) | In vitro verfahren zum einbringen von nukleinsäuren in eine zelle | |
| AU2001287157A1 (en) | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents | |
| WO2003022216A3 (en) | Biaryl substituted purine derivatives as potent antiproliferative agents | |
| FR2792938B1 (fr) | NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV | |
| AR030741A1 (es) | Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa | |
| AU2001261835A1 (en) | Method of treating vaginal dryness with nicotinic acetylcholine receptor agonists | |
| ATE240956T1 (de) | Haloalkoxy-imidazonaphthyridine | |
| TR199802649A2 (xx) | Sikline ba�l� kinazlar�n inhibit�rleri i�in ba�lama e�leri. | |
| BR0108454A (pt) | Métodos para identificação e uso de antagonistas de receptor de adenosina a(2b) papa mediar a proliferação celular em mamìferos | |
| PT1007512E (pt) | 2-aminopiridinas alcoxi-substituidas ramificadas utilizadas como inibidores de nos | |
| WO2001091740A3 (en) | Compositions containing naphthaquinone and an antiproliferative agent | |
| DE69739167D1 (de) | Zusammensetzungen zur modulierung der länge von telomeren | |
| NO20021380D0 (no) | Nye pyrimidin-2,4,6-trion-derivater, fremgangsmåter for deres fremstilling og farmasöytiske midler inneholdende dem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1263440 Country of ref document: EP |